Thalassemia is a disease of erythrocytes that varies largely on its genetic composition and associated clinical presentation. Though some patients may remain asymptomatic, those with a complicated course may experience severe anemia early in childhood, carrying into adulthood and requiring recurrent blood transfusions as a pillar of symptom management. Due to the consequences of ineffective erythropoiesis and frequent transfusions, patients with severe beta thalassemia may be subsequently susceptible to hemochromatosis. In light of the established role of hepcidin and erythroferrone in the pathogenesis of beta thalassemia, this review aims to discuss current clinical trials and studies in the field while presenting clinical implications of the HAMP gene polymorphisms and novel treatments. Research suggested incorporating erythroferrone and serum hepcidin testing as a part of routine workups for beta thalassemia, as they could be a predictive tool for early iron accumulation. Furthermore, ameliorating low hepcidin and high erythroferrone appeared to be crucial in treating beta thalassemia and its complications due to iron overload. Currently, hepcidin-like compounds, such as minihepcidins, LJPC-401, PTG-300, VIT-2763, and agents that promote hepcidin production by inhibiting TMPRSS6 expression or erythroferrone, were shown to be effective in restoring iron homeostasis in preliminary studies. Moreover, the natural bioactives astragalus polysaccharide and icariin have been recently recognized as hepcidin expression inductors.
1 June 2022 in Issues of Rehabilitation, Orthopaedics, Neurophysiology and Sport Promotion - IRONS
Introduction Brain injury (BI) is well-known as a potential cause of irreversible brain damage in humans, often leading to devastating consequences. Currently, there exists no effective treatment in the reversal of BI. However, experimental studies on using hydrogen-rich saline or gas inhalation in animal models has revealed neuroprotective effects; in the setting of BI, hydrogen serves as an antioxidant, anti-inflammatory, and a cytoprotective agent, ultimately aiding in the reversal of cellular damage. The aim of this manuscript is to review existing studies where hydrogen-infused saline was applied in the setting of BI in order to determine whether it should be further studied; if positive, we hope to bring further attention to potential treatments that could serve revolutionary in BI. Methods A literature review of current studies was performed, utilizing the Pubmed database. Any studies which focused on the treatment of BI using hydrogen-rich saline were included; relevant keywords searched were: hydrogen-rich saline; brain injury; molecular hydrogen; hydrogen therapy; animal study. A total of 17 studies were included in this review. Results In reviewing the 17 studies found, one study observed the effect of hydrogen gas inhalation while the other 15 utilized hydrogen-rich saline infusion; each of the 16 studies illustrated that the therapeutic application of hydrogen alleviated BI. Conclusions In conclusion, though there have not yet been any clinical trials in human subjects, preliminary studies on animal models show promise in the treatment of various brain injury (BI) by means of therapeutic hydrogen in saline or gaseous forms.